Company profile: Aditxt
1.1 - Company Overview
Company description
- Provider of biotechnology solutions using novel nucleic acid-based technologies, including AditxtScore for personalized immune profiling; Apoptotic DNA Immunotherapy (ADI) to induce immune tolerance for transplants, autoimmune diseases, and allergies; Adimune for restoring immune tolerance; Pearsanta for personalized diagnostic and monitoring services; and Adivir developing medicines, diagnostics, and vaccines for public health threats.
Products and services
- Apoptotic DNA Immunotherapy (ADI): Nucleic acid-based therapy engineered to induce immune tolerance, aimed at addressing organ transplant rejection, autoimmune diseases, and allergies
- AditxtScore: Platform-level technology delivering a personalized, comprehensive immune system profile, aiding in anticipation of immune responses to viruses, bacteria, allergens, and transplanted organs
- Adivir: Program-level initiative producing medicines, diagnostics, and vaccines for public health threats, including infectious diseases and immunotherapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aditxt
DST Diagnostische Systeme
HQ: Germany
Website
- Description: Provider of in-vitro diagnostic tests and products for allergy and food intolerance, developing, manufacturing and marketing laboratory and point-of-care systems. Offerings include sIgE rapid tests, LIA ALLERGY LINE kits, NutriSMART rapid tests, NutriLAB ELISA kits, over 600 allergen extracts for diagnostic use and IVD manufacturers, and laboratory services with reports and dietary recommendations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DST Diagnostische Systeme company profile →
Evommune
HQ: United States
Website
- Description: Provider of therapeutics to halt progressive disease and address symptoms, focused on chronic inflammatory diseases. Develops EVO756, an oral, highly selective MRGPRX2 inhibitor for chronic spontaneous urticaria despite H1 antihistamines; a PKCθ inhibitor to regulate immune response; collaborative drug discovery with partners like Accutar; and clinical trial programs, including Phase 1 for EVO756.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evommune company profile →
Corbus Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting inflammatory and fibrotic diseases, with programs in oncology and obesity. Pipeline includes CRB-701, a next-generation Nectin-4-targeting ADC in trials for advanced solid tumors; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a peripherally restricted CB1 inverse agonist for obesity with IND planned.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corbus Pharmaceuticals company profile →
Sigyn Therapeutics
HQ: United States
Website
- Description: Provider of therapeutic technologies for inflammatory diseases, including Sigyn Therapy, a blood purification technology extracting pathogens and inflammatory mediators for endotoxemia, sepsis, and drug-resistant infections; ChemoPrep to enhance chemotherapy delivery by depleting tumor-derived extracellular vesicles; ChemoPure to reduce toxicity by removing off-target agents; and ImmunePrep to boost antibody-based immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sigyn Therapeutics company profile →
Sionna Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapies for cystic fibrosis, including SION-638, an NBD1 stabilizer in Phase 1 clinical trials designed to restore CFTR function; SION-109, a small molecule targeting the ICL4–NBD1 interface, in Phase 1; and SION-719, a second series NBD1 stabilizer in preclinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sionna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aditxt
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aditxt
2.2 - Growth funds investing in similar companies to Aditxt
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aditxt
4.2 - Public trading comparable groups for Aditxt
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →